fg casino plus PHILADELPHIA — Heeerrreee’s Kelce! Jason Kelce, the retired Eagles center turned multimedia star, is taking his talents to late-night television as the host of "They Call It Late Night," a new weekly ESPN show filmed in Philadelphia with a limited run leading up to the Super Bowl. Emphasis on late. The show will debut at 1 a.m. on Saturday, Jan. 4, so make sure you set your DVR. “I loved late-night shows, I’ve always loved them,” Kelce said on "Jimmy Kimmel Live!" Thursday night. “I remember sleepovers watching Conan O’Brien with my friends.” Kelce didn’t say much about the format of the show or his first guests, but it will be NFL-focused and air a total of five episodes from Week 18 through the playoffs. “We’re going to have a bunch of guys up there, legends of the game, friends that I played the game with, coaches, celebrities, while also incorporating NFL films,” Kelce said. One thing is clear — not many people are going to be tuning in at 1 a.m. to watch Kelce or anyone else, especially as cord-cutting continues. Instead, the show appears designed to live online, with clips pushed on social media by ESPN’s mighty digital footprint, and available digitally on both ESPN+ and Kelce’s YouTube channel. "They Call It Late Night" will be filmed Friday nights at Union Transfer in Philadelphia, with music provided by brass-heavy Philly party band Snacktime. Tickets will be available through 1iota, but specific information on how to attend a taping hasn’t been released. The name of Kelce’s show is a nod to "They Call it Pro Football," the first full-length documentary produced by NFL films back in 1967, which featured the immortal words of famed Philadelphia broadcaster Jon Facenda: “It starts with a whistle and ends with a gun.” It’s just the latest gig for Kelce, who is in his first season as an NFL studio analyst on ESPN’s "Monday Night Football" pregame show, Monday Night Countdown. He also cohosts "New Heights," the $100 million podcast he began back in 2022 with his brother, Kansas City Chiefs tight end Travis Kelce. There’s also weekly appearances on 94.1 WIP and commercial spots for Wawa, Buffalo Wild Wings, NFL Sunday Ticket, Garage Beer, and more. Oh, and he’s also back with another Philly Special Christmas album alongside Eagles offensive linemen Jordan Mailata and Lane Johnson. Kelce isn’t afraid to stay busy, but being in the spotlight has led to some issues. In May, Kelce and his wife, Kylie, were heckled by a fan in Margate after the duo declined a request for a photo. And earlier this month, Kelce admitted letting his anger get the better of him after a Penn State fan used a homophobic slur in reference to Travis. Kelce reacted by slamming the fan’s phone to the ground and repeating the slur back, which he later apologized for. “It’s a little much at times,” Kelce admitted to The Philadelphia Inquirer during an interview before the start of the NFL season. While the late-night stint might only be five weeks, Kelce signed a multiyear deal with ESPN earlier this year that gives him a lot of flexibility to do different things. In addition to his role as a studio analyst, Kelce spent some time in the booth calling the Eagles’ Week 2 loss to the Atlanta Falcons alongside "Monday Night Football" announcers Joe Buck and Troy Aikman. “I think I got better as it went,” Kelce said following the game. “I think everybody saw Tom Brady’s first-week performance and had a lot of criticism for it ... I got to see firsthand why that’s so hard, for sure.” ©2024 The Philadelphia Inquirer. Visit inquirer.com . Distributed by Tribune Content Agency, LLC.

SOUTHAMPTON, England (AP) — West Ham goalkeeper Lukasz Fabianski is “alert” and conscious after being taken off the field on a stretcher during the team's 1-0 win at Southampton in the on Thursday, manager Julen Lopetegui said. The game was delayed for around eight minutes as Fabianski received treatment on the field at St Mary's Stadium. The 39-year-old Polish goalkeeper was hurt in a collision from a corner and was replaced by Alphonse Areola in the 36th minute. Southampton 'keeper Aaron Ramsdale had run the length of the field to check on Fabianski amid worrying scenes. Fabianski was then greeted by applause as he was taken off with an oxygen mask on, but did not need to go to the hospital. “He had one big knock around the head, around the neck and he was not very sure about his actions. Fortunately the news is he is talking, he is alert, he is conscious,” Lopetegui said. “I talk with him. The doctors say that he feels better and well. I am positive with him. He showed he more or less recovered his sense. I am not afraid. We feared but now he is better and it is a positive feeling because we were very worried.” West Ham, which also saw defender Max Kilman go off in the first half, scored through Jarrod Bowen in the 59th. ___ AP soccer: The Associated Press

SANDY, Utah, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Mountain America Credit Union is proud to announce a recent donation of $14,600 to Operation Warm for the 2024 First Down program with Idaho State Athletics. Through the First Down program, the credit union pledged a donation to Operation Warm for every first down completed by the Idaho State University (ISU) football team during the 2024 season. A Media Snippet accompanying this announcement is available by clicking on this link. Mountain America presented a check to Michael Andrews, senior manager of partnerships at Operation Warm, on November 16, 2024. “A new coat does more than just keep a child warm,” said Andrews. “It boosts their confidence and helps them attend school regularly, ready to learn and succeed. We are grateful for Mountain America’s generous support.” With this donation, Mountain America has now contributed a total of $150,000 to Operation Warm through various programs and events across its multistate footprint. Operation Warm’s mission is to provide confidence, warmth, and hope to children in need through the gift of brand-new winter coats. Recently, Mountain America and Operation Warm partnered to provide 300 coats to preschoolers in Pocatello. In Idaho, 12.5% of individuals under age 18 live below the poverty line, making a warm coat a necessity in winter. The impact of a new coat extends beyond warmth, contributing to a child’s overall well-being and readiness to learn. “We are proud to support Operation Warm through our partnership with Idaho State Athletics, helping to provide new coats to children in need,” said Nathan Anderson, executive vice president and chief operating officer at Mountain America. “Seeing the smiles of the children directly impacted by this work is truly heartwarming and reinforces our dedication to this cause.” To learn more about Operation Warm, please visit operationwarm.org . To learn more about Mountain America’s community involvement, visit macu.com/newsroom . About Mountain America Credit Union With more than 1 million members and $20 billion in assets, Mountain America Credit Union helps its members define and achieve their financial dreams. Mountain America provides consumers and businesses with a variety of convenient, flexible products and services, as well as sound, timely advice. Members enjoy access to secure, cutting-edge mobile banking technology, over 100 branches across multiple states, and more than 50,000 surcharge-free ATMs. Mountain America—guiding you forward. Learn more at macu.com .Okta, Marvell Technology, Campbell's: After-hours movers

This Christmas Hack May Be A Game Changer For Pet Owners in NJ

Luke Littler whitewashes Rob Cross with ridiculous average in Players Championship Finals days after topping £1millionChina's industrial profits extend decline to a fourth straight month, dropping 7.3% in November

Polygon’s Editor’s Letter is a column from Editor-in-Chief Chris Plante that reflects on the video game and entertainment industries, their communities, and Polygon itself. New editions appear in the first week of each month. One of my more neurotic habits is maintaining a spreadsheet that tracks my media diet. Every movie, TV show, comic, sports match, Japanese study session, podcast, and of course video game gets clocked in 15-minute increments. Each day. 365 days a year. Time tracking allows me to analyze where and how I prioritize my time. This year, for example, I played a lot of video games — 106, to be precise. Scanning the spreadsheet, gaming demanded more of my time than any other media — by far. This was intentional. I wanted to keep up with video games in a year of endless new releases. So why does it feel like I missed out? For this month’s Editor’s Letter, I’ll share my takeaways from a year of drinking directly from the hose. And I’ll hopefully make sense of my lingering FOMO along the way. Some of what follows will read like the delirious blather of someone paid to, on some level, play video games for a living. But I hope most of my reaction is relatable. Because with services like Game Pass, an abundance of high-quality free-to-play games, and sales seemingly every other week, the challenge for most people isn’t access to games, but deciding what to play. Or, to put it another way: Everyone’s a game critic now. The cost of loving new games? Missing old ones I’ve written elsewhere about gaming’s current era of abundance , in which each week a dump truck unloads dozens of new releases, burying the previous week’s haul in the process. Despite the Sisyphean nature of this endeavor, I’ve tried my damndest to keep up and have spent most of the year scrounging through the ever-growing heap. Of the 106 games I played in 2024, 95 were released between January and today. The cost of that decision is obvious when you flip the numbers. In 2024 I played only 11 “old” games. Like anybody else, I have a backlog that mocks me every time I open Steam. I’d love to play more of those games someday, but making time to play old games means missing out on new releases, which in turn grows my backlog. One person can’t see the entire picture, but a community can A decade ago, playing 95 new games in a year meant I’d have played every important release, every mildly interesting experiment, and still made room for a few real stinkers. Today, it’s possible I didn’t play your favorite game of the year. Here are some of the games I didn’t play in 2024 that I sincerely wanted to try but for whatever reason didn’t make the time for: Deadlock , Satisfactory , Shin Megami Tensei 5: Vengeance , Warhammer 40,000: Space Marine 2 , Sand Land , Planet Coaster 2 , Core Keeper , Smite 2 , Chained Together , The Outlast Trials , and Persona 3 Reload . And what of living games like Fortnite and Final Fantasy 14 ? No way. These are the sorts of games that, if I played them, would consume every moment of my game time. And so, of the top 10 most-played games on Steam, in 2024, I only played one . You might be aghast. How could the person running Polygon skip some of the most important games in the world? I argue that my experience is a clear justification for Polygon’s existence. Even someone paid, in part, to have an obsessive understanding of video game culture can’t play everything. For the average person, a mix of websites, videos, streams, and podcasts will fill in the gaps. So even if I haven’t played your favorite games, I’ve probably read, watched, or heard something about them. People who only play a few popular games are the norm — for good reason Honestly, I’m exhausted just looking at the list of games I played, which I’ve included in the comments. Trying to keep up with the game du jour (more like du jouer, am I right?) is expensive, time-consuming, and often demands jettisoning one game I’m enjoying to make room for another. As I approach the finish line of my annual marathon, I have a renewed appreciation (jealousy?) for people who opt out of playing the new cool thing, instead committing to one, two, or three games that consume the bulk of their time. As I wrote in a previous Editor’s Letter : According to a report from Newzoo, in 2023 players spent 77% of their playtime on games three years or older. Much of the time players spent on new games went to annualized franchises, like Call of Duty, Madden, and EA FC. A paltry 8% of overall playtime in 2023 went to new games not tied to big, yearly IP. I suspect those stats held true in 2024. Committing to established, particularly free-to-play living games costs far less than a subscription service, let alone new games each week. These games provide constant updates to keep rewarding the time investment. Their familiar loop requires less of their players’ brains, freeing up those players’ mental load to be social with friends on Discord while they play. If you play games as a social activity or a stress relief valve, a few familiar games might be all you need. Video games will be whatever you want them to be Even with everything I’ve written in mind, I wouldn’t have gone about 2024 differently. Hell, as happy as I am to have a slowish December, I’m already looking forward to January, when Steam releases will inevitably ramp back up and my free time will be reclaimed by indie games I’d never heard about until the moment they appear under New & Noteworthy . Because, if you’ll afford me some seasonal saccharine sincerity, this is what childhood me hoped games would become. The variety of games released this year is unmatched compared to the medium’s contemporaries, like film and television. This year, you may play thousands of hours of some of the best role-playing games ever made. Or perhaps you refined your taste in roguelikes like a sommelier honing their palate. You could have flown a perfect re-creation of a commercial jet from Hong Kong to New York, raced in the Monaco Grand Prix, or won MVP at the Super Bowl. In 2024, I played a remake of a game from the 1980s, a pastiche of a game from the 1990s, and a deconstruction of the shooters of the early 2020s. One game turned my Windows OS into a bullet hell. Another gave a squirrel a gun. Games questioned the fundamentals of democracy, the unexamined grief of a pandemic, and the abject joy of stealing a shopping cart and gunning down a hill. Even if I didn’t have this job, I’d still have this gaming diet. Because I find the greatest pleasure in the possibilities. How fortunate we are to experience video games at this moment when there’s something for everyone. Whether that’s enjoying one game all year or a hundred. And six. And counting. I wrote earlier that I hoped to gift y’all with a universal takeaway. And here it is. What I learned from playing an absurd amount of video games over the last 12 months: Whether it’s video games or any other hobby, it’s tempting to look back at how we spent a year and consider everything we could have done instead. To dwell on the gap between our ambitions and our accomplishments. Don’t dwell on what you missed; grow from what you experienced. Because if there’s one thing I’ve learned from tracking my life in a spreadsheet, it’s that there’s never enough time. Gaming Letter from the Editor OpinionHemispheres away from each other, Roc Marciano and The Alchemist are in sync like they’re in the same room. Roc is back home in LA, decompressing from Art Basel, while The Alchemist, who DJs for Eminem, is just landing in Riyadh, Saudi Arabia with the “Rap God.” It’s slightly past midnight for Alchemist, who shows us Zoom attendees a group of people taking pictures of him in front of his hotel. It’s unclear if they’re sneaking shots because, as he suspects, his purple-and-pink ensemble is in stark contrast to their cultural garb or because he’s one of the greatest producers ever to walk the earth. During our conversation, someone walks up to show him love. The international appreciation is a testament to the body of work and production acumen displayed on The Skeleton Key , his new album with Roc Marciano, a follow-up to their 202 collaboration, Elephant Man’s Bones . When I ask when they started working on the 10-track album, which dropped Monday on RocMarci.com (with two bonus songs) and is available on streaming platforms today, Roc clarifies that they have an ongoing creative relationship. Alchemist is always sending beats, and Roc is always writing. Their chemistry is apparent throughout our conversation as they finish and build on each others’ thoughts. That cohesion comes through on the album’s first single, “Chopstick,” which exemplifies The Skeleton Key ’s overall vibe. Throughout the project, Alchemist delivers a canvas that varies from the sixties horror score of “Rauf” to the searing “Street Magic,” where Roc rhymes, “I’m a wolf, I’m aloof, I’m not cool / Despite what you may have assumed, I’m rude,” characteristically delivered with enough steeliness to radiate an entirely different context of “cool.” Their sophomore collaboration comes at the end of banner years for both artists. Alchemist dropped three projects: Heads I Win, Tails You Lose (as Gangrene with Oh No), Black & Whites with Hit-Boy and Big Hit, and The Genuine Articulate — while garnering notable individual placements like Kendrick Lamar’s “Meet The Grahams.” In March, Roc Marciano released his well-regarded album Marciology . He also recently struck a partnership between his Pimpire International label and Roc Nation’s Equity Distribution, which he says puts “a staff” behind his movement in a manner he’s never had before. The two say 2025 is set to be just as prosperous as they’re more artistically focused and empowered on the business end than ever. Editor’s picks The 100 Best TV Episodes of All Time The 250 Greatest Guitarists of All Time The 500 Greatest Albums of All Time The 200 Greatest Singers of All Time Roc Marciano and The Alchemist talked to Rolling Stone about The Skeleton Key , their craft as producers, and the late, great Ka . How’s your 2024 been? Alchemist: It’s been eventful. It’s been more than I could ask for. I can’t speak for Roc, but I feel like we’re both at the place where we’re in a real good hefty stride where it’s like... I won’t say comfort zone because we never try to get too comfortable. I think the turnout and after running for a long time, it feels like we don’t got to speed on the bike anymore; we could kick back and we’re in a flow now. For years, I felt like we were pedaling to create the landscape that we have now. I feel like that’s why it’s... I don’t want to say easy, but it’s like without much effort that we could pull off something like this, basically whenever we want. At what point would you say you felt that flow state? Alchemist: I don’t know if it was a moment, but once we pulled off Elephant Man’s Bones , it felt like we approached it. We got over a hump, and it was like once we both got that and achieved that, collectively, I feel like — and maybe it’s in my head — I could pitch 80 to 90% with Roc if I’m sending him beats or if I got something in mind for him. We’re pretty much in sync. Similar to the flow I had with Prodigy, two completely different artists, but it was like the [similar] rhythm that we were in. It’s rare when you get connections like that with other artists. Related Content A$AP Rocky Teams With J. Cole for New Song 'Ruby Rosary' How Hit-Boy and His Father Big Hit Brought The Family Together on ‘Black & Whites’ Roc Marciano Satiates His Cult Fanbase On ‘Marciology’ How the Rising Rapper MIKE Became More Boundless Than Fan Expectations When would you say y’all started working on this project? Roc Marciano: It’s kind of like we never stopped. We always making music. I’m always sitting on a batch of beats from Al. How much of this one did y’all get a chance to record in person? Roc: Damn, how many joints we did? I think some of the older joints we did from the last project we might’ve did together, I’m not sure. Alchemist: I’m not sure. Some of them we did, but we live in the same city now, too. I feel like we’re damn near in the same studio every morning because of our respective work areas. I could pull up on Roc, or he’d come to my spot, but I think the flow is better when I’m sending him stuff and he’s in his bag over there, taking his time. And then we convene, and we come to my spot or his spot, we take notes, but I think we both have our [own] work environment. I know if Roc is in his element over there, I could just send him stuff, and at his leisure, if it might be three in the morning, it might be eight in the morning, whatever, he’s comfy, and he’s able to do what he does. How intentional was it for this one to have no features? Roc: I don’t know, I don’t care about features, to be honest. [ Laughs ] Features are always an afterthought. Whenever I put features on my album, they’re usually my friends. I never think of an album and be like, “Yo, I need rappers on my album.” I don’t give a fuck about features. Alchemist: It felt like we needed to just do this one. I felt like people that love what we do, I don’t think that they’re like, “Man, that album was good, but we needed some other voices on there.” I feel like if anything, they might be annoyed. It wasn’t one of those events. It felt like a quick mission we needed to pull off, just us in our bag. It naturally became that. And I think it says something too. I was telling Roc yesterday that it’s kind of dope that we were able to get together and make something with this much motion. And get with Josué Thomas , who’s our brother, to do the artwork, and [have] Evidence, also our brother, to do the video. It’s a very self-contained creative product. What is it that’s special and distinct about collaborating with each other? Roc: Alchemist is one of the greats. I always wanted to work with him from back in the days since the Mobb Deep days. So to be able to work with him now, and call him one of my closest friends, I’m blessed to even have this friend circle. So it’s respect and admiration from my side. Alchemist: And I say it all the time, Roc’s my favorite rapper, and I don’t take it lightly because somebody I consider my favorite is one of my close friends. Those are two separate things. I don’t ever let one conflate the other. You are still the God, so when I get an opportunity to work with him or get his ear... Because I know what the hell he’s going to do to these beats, and it’s like, that’s your best friend, if you make beats. Your best friend is the guy who’s going to take your beats and breathe life into them. My friends make me look good. Without these guys, they’d just be a bunch of cool instrumentals. So I value it, and I let them know every time we get a chance to work, like, “Man, thank you.” Roc: Thank you, brother, and I’m lucky myself, man, to make shit, and you always have my back, and make sure I always got a crazy pack from you. Alchemist: That ain’t easy, because Roc’s standards is high. [ Laughs ] I send him a lot of stuff until we land on the right one, but it’s specific. We always find if it takes a couple beats, CDs, or whatever it takes, we going to get to a place where he finds something that moves the pen, and that’s all I can ask for. So, Roc, as a rapper and producer, what does it do for you as an emcee when you can get beats from somebody and just focus on writing? Roc: Yeah, it’s definitely [like] now I don’t have to worry about half the workload. So all I have to do is make sure that I hold up my end of the bargain. When I’m doing my own production, obviously, you got to wear both hats. With this, I get a chance totally focus on what I’m writing, so it’s definitely a much better and easier process for me. On “Street Magic,” you said: “I don’t need my ego stroked.” How important is it not to be driven in your art by external validation? Alchemist: I mean, shit, Roc don’t give a fuck about that. Roc is truly the essence of that. He don’t care with nothing. He does it for the most purest, and not even selfish [reasons], like it’s got to be validated to him first. It got to sit right in his heart, and where he’s at in his career. If somebody else likes it, that shit is trivial for Roc, because I look at stuff. I like to do consumer research and see what’s out there. Roc really, he appreciates it, but he ain’t tripping on that. It’s truthfully [like] we validate this first. We do it for a deeper, higher purpose. So anyone else liking it or validating it after is icing on the cake, you know what I mean? Roc: And I don’t trust people’s tastes anyway. People have bad tastes, so a person with bad taste can’t tell me shit. It’s no need for me to even try to wrap my head around that. I trust my taste over 99% of motherfuckers out here, so have at it. If people love it, they love it. If they don’t, it’s cool. What does your consumer research look like, Al? Alchemist: I do my studies, man. I love watching it. It fascinates me to see that we could press upload on this album, and in Germany, or in Belgium, or Japan, within an hour, there’s people enjoying it. I watch the reviews. If you do reviews, and you got five views on your review, I’m one of the five views. I try to give hope to some of them guys in their room doing those reviews. I watch them, and I like seeing, even if it’s a bad review, the real-time effect of our music on some technology shit. Roc: I got your bad review hanging right here. Alchemist: [ Laughs ] I never thought in my life that I would be in retail. At this point in our careers, we actually run our own labels. We make all the decisions. So it’s on some consumer research type of thing, just seeing what’s working, what isn’t. I check the temperatures out there. That reminds me of the tweet you made recently. It was like, “Yo, if you’re hot, I’ll find you. “ Alchemist: When something that reaches my radar is genuine, I definitely am the type that’ll reach out. I love discovering new artists, or giving somebody who’s a new producer [props like] “Yo, I see you. Keep going crazy.” There’s a producer, Child Actor , who’s really dope that was on my radar. I reached out to him. I didn’t wait for him to hit me like, “Yo, you’re dope. I mess with you.” I’ve done that to a lot of guys because I know what that does, and what that would’ve done for me at the time. And it’s genuine, too, like these are people I get inspiration from. Roc: Yeah, I love doing that, too. I love when you shout people out, and show them love, and they be like, “Yo, wow.” They can’t believe it. You be like, “What, you think I’m corny?” I’m not corny, bro. If you dope, I’ll show you love. It ain’t no skin off my back. So to show love, it don’t cost you nothing. Roc, how does the recent partnership with Roc Nation add to your movement? Roc: It’s just now, there’s a staff behind it. It’s contributing in ways that I feel like the people that were supporting me, they’ve always wanted to see it on a bigger stage and they wanted to see it pushed more to the front. So now that I have a staff and a team behind the projects, because everything that was built, even on our side, we built this without a staff. We weren’t even using marketing dollars and advertisements. This has all been organic. So now, to actually have some people helping out, it’s going to be great, and it’s going to bring more awareness, and it’s bringing more awareness to what we’re doing. Al, I saw you were in one of Eminem’s trailers for his recent album. I was wondering what that experience was like, filming that trailer. Alchemist: It was cool. It was an honor. Anytime they give me the chance to wet my shoes with some acting. And yeah, it’s cool to add that to the list of things that I do. Just being affiliated with Eminem. Obviously, I’m overseas right now on tour with Eminem. Yeah. It’s a blessing to be hitting on all levels. And I could be on the road with him doing this big ass show, come home, hit the studio, and get busy with Roc Marci and make classics and hit the road. I’m blessed to have all these different influences and be able to be with the best of the best in every category. So yeah, it was dope. It was dope when they tapped me to do shit like that because acting, it’s a new challenge for me. Wow. This is a whole world. And even though there’s little bits and things, last year I was filming some stuff with Hit-Boy and Big Hit and it’s fun. It’s like, “Shit. This is tough.” This is not... I respect actors. So it was fun to be able to do that. You mentioned you did something with Big Hit and Hit-Boy. I was wondering if the Eminem thing was your first acting role since Murda Muzik . Alchemist: [Laughs] That was my debut. Trevor, the gun salesman. Probably. And that was a last-minute thing, too. But acting is something that I would love to try my hand at a little more. I have a couple of things coming I don’t want to blow up, but for next year I think it should be interesting. In another interview , you said, “The fun is in danger” in a creative sense. What do you think are some of the next most ambitious creative things you’d like to explore? Roc Marciano: Actually, I want to do more singing. I want to get more into the melody side. I want to make an album like Isaac Hayes, like Black Moses kind of shit. Just fun stuff like that. Experimenting, even though I know they want to box us in with samples and stuff like that. But I’m going to start fucking with some live instrumentation, as well. Just start expanding in every way possible. Whatever they saying we shouldn’t be doing, we going to try our hand at it. Alchemist, I saw that some of your music is not on DSPs anymore. I was wondering if it will be returning to streaming or what’s going on with that? Alchemist: I got some plans. I think people will be surprised, but everything will be back. Yeah, it’s going to come back. Man, remember when Taylor Swift put her music back out? Yeah, re-recorded. Alchemist: Right. Well, I may not re-record, but I realized that the span of my career has touched a lot of different eras and what you think everybody knows, they just might not know. And I feel like me introducing some of the old projects... Like if I re-release First Infantry and do a new video, it’s going to be a whole new first week to a whole world of people. So there’s something there that I got that I’m toying with. And for the ones that knew about it, just keep your mouth shut and act like you don’t know what I’m doing. Roc: Exactly. Shut up. Alchemist: You know what I’m saying? Re-rock. Roc: See, that’s the danger we talking about. You’re not supposed to do that. Ka passed away recently . How are y’all holding up, and what do you think his legacy is? Roc: Well, holding up is a challenge every day when you lose somebody like Ka, so just never going to get over that. But as far as this legacy and everything that we doing, Ka’s firmly planted in it and is a big part of all of this that we started. Ka was the only feature on my first album. He’s been there for this whole ride, and all of the respect and admiration we get, he’s due it as well. It’s cemented: Ka is one of the best lyricists to ever walk the planet. And I’m not saying that because he passed because I was saying that while he was living. And that’s just what it is. That’s the truth. And he’s going to be forever missed. Alchemist: Ka was one of my biggest inspirations, and I still maintain that even more now. Definitely something I was able to tell him while he was here and let him know I met him through Roc. But I never let him think for a minute that I didn’t know that he was something special. And from the whole aspect of him producing, writing, and filming his own videos, that really inspired me. I felt like he was a true artist, and there was no filter between him. Sometimes you got to explain your shit to an engineer. You got to explain your shit to a video director. There was none of that. He bypassed all that. His art was exactly from the visual. You could smell, taste, and touch what was his pure thought. And that, to this day, still motivates me, especially on the video side of things. I feel like this type of project is something that we had to do, even in the spirit of Ka, in the passing of it. Man this is something that will make him proud. And I definitely felt like we were getting his blessings from above, as far as to keep going and keep alive in the artistry that we’ve been given. We all have a limited time on this earth, so every day matters. And Ka proved that. Look at how great his discography is in a short period of time. It’s almost scary. Like, “Damn, he did his thing.” But we never know when we’re going to check out. He’s always going to be a big inspiration, I know, to Roc and to me, as well. What are y’all looking forward to most in 2025? Roc: More great music and just enjoying life and our families and adding on to the legacy that we’ve been building. That’s what I’m looking forward to. Alchemist: Yeah, I can’t even lie, it looks already like next year could potentially be the biggest year ever for me. And really, to be honest, just based on the things I have lined up already, I’m just making sure I stay healthy, man. That’s all I care about now. I want to stay here because [there are] too much blessings around the corner. So [that’s] what I’m thinking about, making sure that we are in the right shape, mind, body, and soul to receive all the blessings that are right around the corner from the work. It wasn’t like they fell out of the sky. Roc: Ain’t that what I always be on you about? Alchemist: That’s it. Roc be checking in on me every now and then like, “Yo, you good? You sleeping? You eating good?” Because he knows I might work to the point where I’m not even paying attention to that shit. [ Laughs ] But as we get older, these are the true things. The only thing on my mind, is I got to stay good so I can enjoy all this shit. Because the hard work is starting to pay off and it’s only making us work harder.

Common Warts Pipeline Insights 2024: Therapies, Clinical Trials, Mechanism of Action, Route of Administration, and Developments | Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, 11-27-2024 07:41 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Common Warts pipeline constitutes 5+ key companies continuously working towards developing 5+ Common Warts treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Common Warts Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Common Warts Market. The Common Warts Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Common Warts Pipeline Report: https://www.delveinsight.com/sample-request/common-warts-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Common Warts treatment therapies with a considerable amount of success over the years. •Common Warts companies working in the treatment market are Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others, are developing therapies for the Common Warts treatment •Emerging Common Warts therapies in the different phases of clinical trials are- CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others are expected to have a significant impact on the Common Warts market in the coming years. •In August 2024, Verrica Pharmaceuticals shared promising new data from its Phase 2 study of the oncolytic peptide VP-315 for treating basal cell carcinoma. With positive safety and efficacy results, the company believes VP-315 could potentially become a first-line treatment for basal cell carcinoma. Detailed results will be presented at an upcoming KOL event. Additionally, Verrica has amended its agreement with Torii Pharmaceutical Inc. Ltd., facilitating the advancement of YCANTH into Phase 3 trials for treating common warts. Common warts represent a major unmet need in dermatology, and YCANTH could set a new standard of care for this condition, as no FDA-approved therapies currently exist. •In May 2024, Verrica Pharmaceuticals announced that it has revised its collaboration and licensing agreement with Torii Pharmaceutical Co. Ltd. to co-fund the global Phase 3 clinical trial for YCANTH® in the treatment of common warts. Under the revised terms, the two companies will equally share the costs of the trial, with Torii covering Verrica's portion as an offset to future payment obligations related to regulatory milestones and sales of YCANTH for molluscm contagiosum and common warts in Japan. Additionally, Torii is required to make an $8.0 million milestone payment to Verrica upon dosing the first patient in Japan during the Phase 3 trial, which is expected to begin in the first half of 2025. Common Warts Overview Common warts are small, noncancerous skin growths caused by the human papillomavirus (HPV). They typically appear on the hands, fingers, or other areas prone to minor cuts and abrasions. Common warts have a rough, grainy texture and are often flesh-colored, with tiny black dots (clotted blood vessels) on the surface. Get a Free Sample PDF Report to know more about Common Warts Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/common-warts-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Common Warts Drugs Under Different Phases of Clinical Development Include: •CANDIN: Nielsen BioSciences/Maruho •VP-102: Verrica Pharmaceutical •FIT039: Kino Pharma/ Iwaki Pharmaceutical •A-101: Aclaris Therapeutics, Inc. •KNP2002: KinoPharma Inc. •10% EISO: ViroXis Corporation •CLS006: Maruho Co., Ltd. •VDMN-21: Veradermics, Inc. •Resiquimod: Graceway Pharmaceuticals, LLC •Imiquimod: MEDA Pharma •Picato: LEO Pharma Common Warts Route of Administration Common Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Oral •Parenteral •Intravenous •Subcutaneous •Topical Common Warts Molecule Type Common Warts Products have been categorized under various Molecule types, such as •Monoclonal Antibody •Peptides •Polymer •Small molecule •Gene therapy Common Warts Pipeline Therapeutics Assessment •Common Warts Assessment by Product Type •Common Warts By Stage and Product Type •Common Warts Assessment by Route of Administration •Common Warts By Stage and Route of Administration •Common Warts Assessment by Molecule Type •Common Warts by Stage and Molecule Type DelveInsight's Common Warts Report covers around 5+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Common Warts product details are provided in the report. Download the Common Warts pipeline report to learn more about the emerging Common Warts therapies at: https://www.delveinsight.com/sample-request/common-warts-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Common Warts Therapeutics Market include: Key companies developing therapies for Common Warts are - Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, Maruho Co., Aclaris Therapeutics, and others. Common Warts Pipeline Analysis: The Common Warts pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Common Warts with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Common Warts Treatment. •Common Warts key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Common Warts Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Common Warts market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Common Warts drugs and therapies- https://www.delveinsight.com/sample-request/common-warts-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Common Warts Pipeline Market Strengths •The rising prevalence of warts is encourages companies in the life sciences industry to focus on research and development of new drugs for warts treatment. There is a continuous need for new, innovative therapeutic approaches for better treatment outcomes. •An increase in emerging new drugs for the treatment of warts will lead to better patient outcomes in the coming years. Common Warts Pipeline Market Opportunities •Recent studies have shown the safe and efficacious role of Zinc supplementation in warts clearance, particularly for patients who have not responded to treatments previously. •Secondary research on the warts therapeutics market suggests that the market is saturated with limited drug opportunities providing the key Pharma players a successful domain to work with utmost robustness Scope of Common Warts Pipeline Drug Insight •Coverage: Global •Key Common Warts Companies: Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others •Key Common Warts Therapies: CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others •Common Warts Therapeutic Assessment: Common Warts current marketed and Common Warts emerging therapies •Common Warts Market Dynamics: Common Warts market drivers and Common Warts market barriers Request for Sample PDF Report for Common Warts Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/common-warts-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Common Warts Report Introduction 2. Common Warts Executive Summary 3. Common Warts Overview 4. Common Warts- Analytical Perspective In-depth Commercial Assessment 5. Common Warts Pipeline Therapeutics 6. Common Warts Late Stage Products (Phase II/III) 7. Common Warts Mid Stage Products (Phase II) 8. Common Warts Early Stage Products (Phase I) 9. Common Warts Preclinical Stage Products 10. Common Warts Therapeutics Assessment 11. Common Warts Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Common Warts Key Companies 14. Common Warts Key Products 15. Common Warts Unmet Needs 16 . Common Warts Market Drivers and Barriers 17. Common Warts Future Perspectives and Conclusion 18. Common Warts Analyst Views 19. Appendix 20. About DelveInsight Related Reports: Common Warts Market https://www.delveinsight.com/report-store/common-warts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Common Warts Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Common Warts Epidemiology https://www.delveinsight.com/report-store/common-warts-epidemiology-forecast-report?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Common Warts Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Latest Reports: •Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market •Sglt2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market •Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight •Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market •Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market •Peritoneal Dialysis Equipment Market: https://www.delveinsight.com/report-store/peritoneal-dialysis-equipment-market •Drug-eluting Stents Market Market: https://www.delveinsight.com/report-store/drug-eluting-stents-market •Sinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market •Pd-1 & Pdl1 Market: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.

Odia Actor Manoj Mishra, Director Bobby Islam Fight Outside Police Station, Video Goes ViralBoston College 81, Holy Cross 55

China is armed and ready for trade war 2.0 with Donald TrumpMAP Meeting Evolves into MedSpa Pro, Builds Momentum for Record-Breaking 2025

49ers’ Kyle Shanahan isn’t ready to talk about 2025 season yetNEW YORK (AP) — U.S. stocks climbed Thursday after market superstar Nvidia and another round of companies said they’re making even fatter profits than expected. The S&P 500 pulled 0.5% higher after flipping between gains and losses several times during the day. Banks, smaller companies and other areas of the stock market that tend to do best when the economy is strong helped lead the way, while bitcoin briefly broke above $99,000. Crude oil, meanwhile, continued to rise. The Dow Jones Industrial Average jumped 461 points, or 1.1%, and the Nasdaq composite edged up by less than 0.1%. Nvidia rose just 0.5% after beating analysts’ estimates for profit and revenue yet again, but it was still the strongest force pulling the S&P 500 upward. It also gave a forecast for revenue in the current quarter that topped most analysts’ expectations due to voracious demand for its chips used in artificial-intelligence technology. Its stock initially sank in afterhours trading Wednesday following the release of the results. Some investors said the market might have been looking for Nvidia’s revenue forecast to surpass expectations by even more. But its stock recovered in premarket trading Thursday, and Wedbush analyst Dan Ives said it was another “flawless” profit report provided by Nvidia and CEO Jensen Huang, whom Ives calls “the Godfather of AI.” The stock meandered through Thursday as well, dragging the S&P 500 and other indexes back and forth. How Nvidia’s stock performs has more impact than any other because it’s grown into Wall Street’s most valuable company at roughly $3.6 trillion. The frenzy around AI is sweeping up other stocks, and Snowflake jumped 32.7% after reporting stronger results for the latest quarter than analysts expected. The company, whose platform helps customers get a better view of all their silos of data and use AI, also reported stronger revenue growth than expected. BJ’S Wholesale Club rose 8.3% after likewise delivering a bigger profit than expected. That may help calm worries about how resilient U.S. shoppers can remain, given high prices across the economy and still-high interest rates. A day earlier, Target tumbled after reporting sluggish sales in the latest quarter and giving a dour forecast for the holiday shopping season. It followed Walmart , which gave a much more encouraging outlook. Nearly 90% of the stocks in the S&P 500 ended up rising Thursday, and the gains were even bigger among smaller companies. The Russell 2000 index of smaller stocks jumped a market-leading 1.7%. Google’s parent company, Alphabet, helped keep indexes in check. It fell 4.7% after U.S. regulators asked a judge to break up the tech giant by forcing it to sell its industry-leading Chrome web browser. In a 23-page document filed late Wednesday, the U.S. Department of Justice called for sweeping punishments that would include restrictions preventing Android from favoring its own search engine. Regulators stopped short of demanding Google sell Android but left the door open to it if the company’s oversight committee continues to see evidence of misconduct. All told, the S&P 500 rose 31.60 points to 5,948.71. The Dow jumped 461.88 to 43,870.35, and the Nasdaq composite added 6.28 to 18,972.42. In the crypto market, bitcoin eclipsed $99,000 for the first time before pulling back toward $98,000, according to CoinDesk. It’s more than doubled so far this year, and its climb has accelerated since Election Day. President-elect Donald Trump has pledged to make the country “the crypto capital of the planet” and create a “strategic reserve” of bitcoin. Bitcoin got a further boost after Gary Gensler, the chair of the Securities and Exchange Commission, said Thursday he would step down in January . Gensler has pushed for more protections for crypto investors. Bitcoin and related investment have a notorious history of big price swings in both directions. MicroStrategy, a company that’s been raising cash expressly to buy bitcoin, saw an early Thursday gain of 14.6% for its stock quickly disappear. It finished the day with a loss of 16.2%. In the oil market, a barrel of benchmark U.S. crude rose 2% to bring its gain for the week to 4.8%. Brent crude, the international standard, climbed 1.8%. Oil has been rising amid escalations in the Russia-Ukraine war. In stock markets abroad, shares of India’s Adani Enterprises plunged 22.6% Thursday after the U.S. charged founder Gautam Adani in a federal indictment with securities fraud and conspiracy to commit securities and wire fraud. The businessman and one of the world’s richest people is accused of concealing that his company’s huge solar energy project on the subcontinent was being facilitated by an alleged bribery scheme. Stock indexes elsewhere in Asia and Europe were mixed. In the bond market, the yield on the 10-year Treasury inched up to 4.43% from 4.41% late Wednesday following some mixed reports on the U.S. economy. One said fewer U.S. workers applied for unemployment benefits last week in the latest signal that the job market remains solid. Another report, though, said manufacturing in the mid-Atlantic region unexpectedly shrank. Sales of previously occupied homes, meanwhile, strengthened last month by more than expected. AP Business Writers Matt Ott and Yuri Kageyama contributed.